Alzheimers

Two powerful congressional committees investigating the controversial federal approval of Biogen's Alzheimer's drug Aduhelm requested extensive information and documents from the Food and Drug Administration in a letter published Thursday,…

Aduhelm from BiogenSource: BiogenBiogen's Alzheimer's drug Aduhelm made $ 2 million in sales in the first few weeks after its approval, the company said Thursday when it released its second quarter results along with an open letter about…

In a conspicuous concern about the approval of the controversial new Alzheimer's drug Aduhelm, the Cleveland Clinic said Wednesday evening that it would not give it to patients.The clinic, one of the largest and most respected medical…

A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesActing Commissioner of the Food and Drug Administration, Dr. Janet Woodcock, on Wednesday,…

The Food and Drug Administration on Friday called for a federal investigation into the process that led to the approval of a new drug for Alzheimer's disease that has sparked harsh criticism from lawmakers and the medical community.In a…

When the F.D.A. approved Aduhelm a month ago, its original label had said that the drug is “for the treatment of Alzheimer’s disease.” The surprisingly broad label caused a storm of concern among many Alzheimer’s experts, even those who had…

“It puts us in a bad place,” agreed Dr. Karina Bishop, a geriatrician at the University of Nebraska Medical Center. Ethically, she added, “if this drug was available right now, I would not feel able to prescribe it.”Even as individual…

Dr. Selloway, a research director on the site for studies of the drug, was not paid for this work but has received research and consulting fees from Biogen. He said doctors should only use the drug on patients whose status matches those…

Aduhelm from BiogenSource: BiogenThe FDA approval of Biogen's Alzheimer's drug Aduhelm marked a milestone in Dr. Paul Aisen. The director of the Alzheimer's Therapeutic Research Institute at USC has focused on the treatment of…

In addition to the United States, Biogen has asked regulators in Australia, Brazil, Canada, the European Union, Japan and Switzerland to review the drug.The U.S. approval is a crucial victory for a company that has been counting on Aduhelm…